Increased Plasmatic Levels of PSA-Expressing Exosomes Distinguish Prostate Cancer Patients from Benign Prostatic Hyperplasia: A Prospective Study
Prostate Specific Antigen (PSA) fails to discriminate between benign prostatic hyperplasia (BPH) and Prostate Cancer (PCa), resulting in large numbers of unnecessary biopsies and missed cancer diagnoses. Nanovesicles called exosomes are directly detectable in patient plasma and here we explore the p...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2019-09-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/11/10/1449 |
| _version_ | 1797761632525352960 |
|---|---|
| author | Mariantonia Logozzi Daniela F. Angelini Alessandro Giuliani Davide Mizzoni Rossella Di Raimo Martina Maggi Alessandro Gentilucci Vittorio Marzio Stefano Salciccia Giovanna Borsellino Luca Battistini Alessandro Sciarra Stefano Fais |
| author_facet | Mariantonia Logozzi Daniela F. Angelini Alessandro Giuliani Davide Mizzoni Rossella Di Raimo Martina Maggi Alessandro Gentilucci Vittorio Marzio Stefano Salciccia Giovanna Borsellino Luca Battistini Alessandro Sciarra Stefano Fais |
| author_sort | Mariantonia Logozzi |
| collection | DOAJ |
| description | Prostate Specific Antigen (PSA) fails to discriminate between benign prostatic hyperplasia (BPH) and Prostate Cancer (PCa), resulting in large numbers of unnecessary biopsies and missed cancer diagnoses. Nanovesicles called exosomes are directly detectable in patient plasma and here we explore the potential use of plasmatic exosomes expressing PSA (Exo-PSA) in distinguishing healthy individuals, BPH, and PCa. Exosomes were obtained from plasma samples of 80 PCa, 80 BPH, and 80 healthy donors (CTR). Nanoparticle Tracking Analysis (NTA), immunocapture-based ELISA (IC-ELISA), and nanoscale flow-cytometry (NSFC), were exploited to detect and characterize plasmatic exosomes. Statistical analysis showed that plasmatic exosomes expressing both CD81 and PSA were significantly higher in PCa as compared to both BPH and CTR, reaching 100% specificity and sensitivity in distinguishing PCa patients from healthy individuals. IC-ELISA, NSFC, and Exo-PSA consensus score (EXOMIX) showed 98% to 100% specificity and sensitivity for BPH-PCa discrimination. This study outperforms the conventional PSA test with a minimally invasive widely exploitable approach. |
| first_indexed | 2024-03-12T19:15:58Z |
| format | Article |
| id | doaj.art-3b822bdd1ced473bb5a3b68008d6f2d5 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-12T19:15:58Z |
| publishDate | 2019-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-3b822bdd1ced473bb5a3b68008d6f2d52023-08-02T05:31:31ZengMDPI AGCancers2072-66942019-09-011110144910.3390/cancers11101449cancers11101449Increased Plasmatic Levels of PSA-Expressing Exosomes Distinguish Prostate Cancer Patients from Benign Prostatic Hyperplasia: A Prospective StudyMariantonia Logozzi0Daniela F. Angelini1Alessandro Giuliani2Davide Mizzoni3Rossella Di Raimo4Martina Maggi5Alessandro Gentilucci6Vittorio Marzio7Stefano Salciccia8Giovanna Borsellino9Luca Battistini10Alessandro Sciarra11Stefano Fais12Department of Oncology and Molecular Medicine, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Rome, ItalyNeuroimmunology Unit, IRCCS Santa Lucia Foundation, 00179 Rome, ItalyEnvironment and Health Department Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Rome, ItalyDepartment of Oncology and Molecular Medicine, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Rome, ItalyDepartment of Oncology and Molecular Medicine, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Rome, ItalyDepartment of Urology, Policlinico Umberto I, Università La Sapienza, Viale dell’Università 33, 00161 Rome, ItalyDepartment of Urology, Policlinico Umberto I, Università La Sapienza, Viale dell’Università 33, 00161 Rome, ItalyDepartment of Urology, Policlinico Umberto I, Università La Sapienza, Viale dell’Università 33, 00161 Rome, ItalyDepartment of Urology, Policlinico Umberto I, Università La Sapienza, Viale dell’Università 33, 00161 Rome, ItalyNeuroimmunology Unit, IRCCS Santa Lucia Foundation, 00179 Rome, ItalyNeuroimmunology Unit, IRCCS Santa Lucia Foundation, 00179 Rome, ItalyDepartment of Urology, Policlinico Umberto I, Università La Sapienza, Viale dell’Università 33, 00161 Rome, ItalyDepartment of Oncology and Molecular Medicine, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Rome, ItalyProstate Specific Antigen (PSA) fails to discriminate between benign prostatic hyperplasia (BPH) and Prostate Cancer (PCa), resulting in large numbers of unnecessary biopsies and missed cancer diagnoses. Nanovesicles called exosomes are directly detectable in patient plasma and here we explore the potential use of plasmatic exosomes expressing PSA (Exo-PSA) in distinguishing healthy individuals, BPH, and PCa. Exosomes were obtained from plasma samples of 80 PCa, 80 BPH, and 80 healthy donors (CTR). Nanoparticle Tracking Analysis (NTA), immunocapture-based ELISA (IC-ELISA), and nanoscale flow-cytometry (NSFC), were exploited to detect and characterize plasmatic exosomes. Statistical analysis showed that plasmatic exosomes expressing both CD81 and PSA were significantly higher in PCa as compared to both BPH and CTR, reaching 100% specificity and sensitivity in distinguishing PCa patients from healthy individuals. IC-ELISA, NSFC, and Exo-PSA consensus score (EXOMIX) showed 98% to 100% specificity and sensitivity for BPH-PCa discrimination. This study outperforms the conventional PSA test with a minimally invasive widely exploitable approach.https://www.mdpi.com/2072-6694/11/10/1449prostate cancer (pca)benign prostatic hyperplasia (bph)exosomeselisananoscale flow cytometry |
| spellingShingle | Mariantonia Logozzi Daniela F. Angelini Alessandro Giuliani Davide Mizzoni Rossella Di Raimo Martina Maggi Alessandro Gentilucci Vittorio Marzio Stefano Salciccia Giovanna Borsellino Luca Battistini Alessandro Sciarra Stefano Fais Increased Plasmatic Levels of PSA-Expressing Exosomes Distinguish Prostate Cancer Patients from Benign Prostatic Hyperplasia: A Prospective Study Cancers prostate cancer (pca) benign prostatic hyperplasia (bph) exosomes elisa nanoscale flow cytometry |
| title | Increased Plasmatic Levels of PSA-Expressing Exosomes Distinguish Prostate Cancer Patients from Benign Prostatic Hyperplasia: A Prospective Study |
| title_full | Increased Plasmatic Levels of PSA-Expressing Exosomes Distinguish Prostate Cancer Patients from Benign Prostatic Hyperplasia: A Prospective Study |
| title_fullStr | Increased Plasmatic Levels of PSA-Expressing Exosomes Distinguish Prostate Cancer Patients from Benign Prostatic Hyperplasia: A Prospective Study |
| title_full_unstemmed | Increased Plasmatic Levels of PSA-Expressing Exosomes Distinguish Prostate Cancer Patients from Benign Prostatic Hyperplasia: A Prospective Study |
| title_short | Increased Plasmatic Levels of PSA-Expressing Exosomes Distinguish Prostate Cancer Patients from Benign Prostatic Hyperplasia: A Prospective Study |
| title_sort | increased plasmatic levels of psa expressing exosomes distinguish prostate cancer patients from benign prostatic hyperplasia a prospective study |
| topic | prostate cancer (pca) benign prostatic hyperplasia (bph) exosomes elisa nanoscale flow cytometry |
| url | https://www.mdpi.com/2072-6694/11/10/1449 |
| work_keys_str_mv | AT mariantonialogozzi increasedplasmaticlevelsofpsaexpressingexosomesdistinguishprostatecancerpatientsfrombenignprostatichyperplasiaaprospectivestudy AT danielafangelini increasedplasmaticlevelsofpsaexpressingexosomesdistinguishprostatecancerpatientsfrombenignprostatichyperplasiaaprospectivestudy AT alessandrogiuliani increasedplasmaticlevelsofpsaexpressingexosomesdistinguishprostatecancerpatientsfrombenignprostatichyperplasiaaprospectivestudy AT davidemizzoni increasedplasmaticlevelsofpsaexpressingexosomesdistinguishprostatecancerpatientsfrombenignprostatichyperplasiaaprospectivestudy AT rosselladiraimo increasedplasmaticlevelsofpsaexpressingexosomesdistinguishprostatecancerpatientsfrombenignprostatichyperplasiaaprospectivestudy AT martinamaggi increasedplasmaticlevelsofpsaexpressingexosomesdistinguishprostatecancerpatientsfrombenignprostatichyperplasiaaprospectivestudy AT alessandrogentilucci increasedplasmaticlevelsofpsaexpressingexosomesdistinguishprostatecancerpatientsfrombenignprostatichyperplasiaaprospectivestudy AT vittoriomarzio increasedplasmaticlevelsofpsaexpressingexosomesdistinguishprostatecancerpatientsfrombenignprostatichyperplasiaaprospectivestudy AT stefanosalciccia increasedplasmaticlevelsofpsaexpressingexosomesdistinguishprostatecancerpatientsfrombenignprostatichyperplasiaaprospectivestudy AT giovannaborsellino increasedplasmaticlevelsofpsaexpressingexosomesdistinguishprostatecancerpatientsfrombenignprostatichyperplasiaaprospectivestudy AT lucabattistini increasedplasmaticlevelsofpsaexpressingexosomesdistinguishprostatecancerpatientsfrombenignprostatichyperplasiaaprospectivestudy AT alessandrosciarra increasedplasmaticlevelsofpsaexpressingexosomesdistinguishprostatecancerpatientsfrombenignprostatichyperplasiaaprospectivestudy AT stefanofais increasedplasmaticlevelsofpsaexpressingexosomesdistinguishprostatecancerpatientsfrombenignprostatichyperplasiaaprospectivestudy |